Cantor Fitzgerald has lowered its price target for Ultragenyx Pharmaceutical (RARE) from $103 to $33, while maintaining an 'Overweight' rating. This significant price target reduction, despite the maintained positive rating, suggests a re-evaluation of the company's near-term valuation prospects.
Cantor Fitzgerald analyst Kristen Kluska has significantly reduced the price target for Ultragenyx Pharmaceutical (RARE) from $103 to $33, a substantial cut of approximately 68%. Despite this drastic reduction, the 'Overweight' rating was maintained. This indicates that while the analyst still sees long-term potential or relative outperformance, the near-term valuation has been severely re-assessed, likely due to new data, market conditions, or pipeline developments not explicitly detailed in this filing. This could lead to short-term negative pressure on RARE's stock as investors react to the lowered valuation expectations, even if the long-term outlook remains somewhat positive from the analyst's perspective. For traders, this presents a potential short-term downside risk or an opportunity for those who believe the price target cut is an overreaction and the 'Overweight' rating holds more weight.